Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Shanghai Zhongshan Hospital
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07309419CT.gov A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT07321613CT.gov Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients | — | Completed | — | — | — |
NCT01924624CT.gov Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT02447679CT.gov Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence | — | Completed | — | — | — |
NCT00971126CT.gov Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC) | — | Terminated | — | — | — |
NCT00921531CT.gov Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT00728078CT.gov Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT00519688CT.gov UFUR Plus Thalidomide for Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT00155272CT.gov Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT00225290CT.gov Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Thalidomide (this asset) | Shanghai Zhongshan Hospital | P3 | B · 61 |
| Adefovir | Bukwang Pharmaceutical | P4 | BBB |
| Huaier Granule | Tongji Hospital | P4 | BBB |
| Fluorouracilum | Li Qiang | P4 | BBB |
| Oxaliplatin | Li Qiang | P4 | BBB |
| Theprubicin | RWTH Aachen University | P4 | BB |
| Adriamycin | VA Office of Research and Development | P4 | BB |
| nrt6003 | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Epirubicin | Fudan University | P4 | BB |
+42 more in the Hepatocellular Carcinoma cohort
Other indications for Thalidomide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Central Nervous System Neoplasm | — | P2 | BB · 70 |
| Plasma Cell Myeloma | — | P4 | BB · 68 |
| Uveal Melanoma | — | P2 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Thalidomide in Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/thalidomide-hepatocellular-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →